China's BCI Tech Advancement

China is rapidly advancing its brain-computer interface (BCI) technology, with predictions of practical public use within three to five years. Beijing has designated BCIs as a core strategic industry in its new five-year plan, aiming for major technical breakthroughs by 2027 and the cultivation of world-class firms by 2030. China is the second country to launch invasive BCI human trials, matching the US with over 10 active trials and plans to enroll more than 50 patients this year. The government has also integrated BCI treatments into national medical insurance in pilot provinces, with the domestic market projected to reach $809 million by 2027. Experts like Yao Dezhong highlight China's advantages, including its large population, patient demand, cost-effective industrial chain, and STEM talent pool. While US startups like Neuralink focus on invasive chips, Chinese researchers are exploring invasive, semi-invasive, and non-invasive BCIs, with the goal of achieving similar technological feats domestically.